FBXO4: A Potential Drug Target Or Biomarker (G26272)

Target Name: FBXO4

NCBI ID: G26272

FBXO4

FBXO4: A Potential Drug Target Or Biomarker

FBXO4, also known as FBXO4 variant 1, is a protein that is expressed in various tissues throughout the body. It is a member of the F box protein family, which is a family of proteins that are involved in various cellular processes. FBXO4 has been identified as a potential drug target or biomarker due to its unique structure and the diseases it is associated with.

FBXO4 is a 21-kDa protein that is expressed in the brain, heart, and skeletal muscles. It is composed of 21 amino acid residues and has a calculated pI of 1.9. FBXO4 is highly conserved, with only one reported difference at amino acid position 117. This suggests that it has a relatively stable structure and that any changes in its expression or function would be unlikely to be dramatic.

One of the key features of FBXO4 is its ability to interact with various molecules. It has been shown to interact with a variety of proteins, including the protein kinase Bcr/Abl, which is involved in the regulation of cell growth and survival. This interaction suggests that FBXO4 may be a useful target for drugs that are designed to inhibit the activity of Bcr/Abl.

Another potential mechanism by which FBXO4 may be targeted by drugs is its role in the regulation of cellular processes that are important for the development and progression of certain diseases. For example, FBXO4 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This suggests that drugs that are designed to disrupt angiogenesis may be effective against diseases that are characterized by the formation of new blood vessels.

FBXO4 is also thought to be involved in the regulation of cellular signaling pathways that are important for the survival and growth of tissues. For example, it has been shown to be involved in the regulation of the TGF-β pathway, which is a signaling pathway that is involved in the regulation of cell growth and differentiation. This suggests that drugs that are designed to disrupt TGF-β signaling pathways may be effective against diseases that are characterized by the over-expression of TGF-β.

In addition to its potential role as a drug target or biomarker, FBXO4 is also of interest as a potential therapeutic agent. Studies have shown that FBXO4 has been shown to have neuroprotective properties, particularly in the context of neurodegenerative diseases. For example, FBXO4 has has been shown to protect against the neurotoxicity of 尾-amyloid in rat cerebral cortical neurons, which is a common model of Alzheimer's disease. This suggests that FBXO4 may be an effective agent for the treatment of neurodegenerative diseases.

Overall, FBXO4 is a protein that is expressed in various tissues throughout the body and has been shown to interact with a variety of molecules. Its unique structure and its potential role as a drug target or biomarker make it an intriguing molecule for further study. Further research is needed to fully understand the function and potential of FBXO4 in the context of disease.

Protein Name: F-box Protein 4

Functions: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:18598945, PubMed:10531035, PubMed:29142209, PubMed:20181953). Promotes ubiquitination of CCND1 and its subsequent proteasomal degradation (PubMed:18598945). Recognizes TERF1 and promotes its ubiquitination together with UBE2D1 (PubMed:16275645, PubMed:20159592). Promotes ubiquitination of FXR1 following phosphorylation of FXR1 by GSK3B, leading to FXR1 degradation by the proteasome (PubMed:29142209)

The "FBXO4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets